Phase III Safety Evaluation of Cyclosporine 0.1% Ophthalmic Emulsion Administered Twice Daily to Dry Eye Disease Patients for Up to 3 Years
Authors:
- Stephen C. PflugfelderSPStephen C. Pflugfelder
- Joseph TauberJTJoseph Tauber
- Gary N. FoulksGFGary N. Foulks
- 1 October 2005
- journal article
- clinical trial
- Published by Elsevier in Ophthalmology
- Vol. 112 (10) , 1790-1794
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- The role of the lacrimal functional unit in the pathophysiology of dry eyeExperimental Eye Research, 2004
- Blood Concentrations of Cyclosporin A During Long-Term Treatment With Cyclosporin A Ophthalmic Emulsions in Patients With Moderate to Severe Dry Eye DiseaseJournal of Ocular Pharmacology and Therapeutics, 2002
- Goblet Cell Numbers and Epithelial Proliferation in the Conjunctiva of Patients With Dry Eye Syndrome Treated With CyclosporineArchives of Ophthalmology (1950), 2002
- Tear film MMP accumulation and corneal diseaseBritish Journal of Ophthalmology, 2001
- Analysis of Topical Cyclosporine Treatment of Patients With Dry Eye SyndromeEffect on Conjunctival LymphocytesArchives of Ophthalmology (1950), 2000
- The Diagnosis and Management of Dry EyeCornea, 2000
- Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye diseaseOphthalmology, 2000
- Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease11Reprint requests to: Linda Lewis, 575 Anton Blvd, Suite 900, Costa Mesa, CA 92626.Ophthalmology, 2000
- The Pathology of Dry EyeCornea, 1998
- Calcineurin and the biological effect of cyclosporine and tacrolimusTransplantation Proceedings, 1998